الفهرس | Only 14 pages are availabe for public view |
Abstract Multimorbid patients who suffer fromthe coexistence of two or more chronic diseases, especially in elderly patients, may encounter more severe side effects or less effective medication outcomes due to drug-drug interactions. As statins are commonly prescribed with dihydropyridine calcium channel blockers (DHP-CCBs) in patients with cardiovascular or cerebrovascular diseases, patients suffer often from augmented efficacy/effect of one or both of them. It might be due to pharmacokinetic interactions between statins and DHP-CCBs. The present study was designed to investigate the potential pharmacokinetic interactions of two commonly used statins viz., simvastatin and pravastatin, and the possible effect of each statin on the pharmacokinetic parameters of nimodipine. This studyaimed to elucidate the possible mechanism of interaction as simvastatin and nimodipine are metabolized via the CYP 3A4 in rats, while pravastatin is not significantly affected by CYP biotransformation.Besides, the present study compared the different effects of simvastatin and pravastatin on rhabdomyolysis that is initially provoked by statins, through studying the creatine kinase (CK) as a biomarker of rhabdomyolysis |